Literature DB >> 31257205

Predicting survival in light chain amyloidosis.

Giovanni Palladini1, Paolo Milani1, Giampaolo Merlini1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31257205      PMCID： PMC6601088          DOI： 10.3324/haematol.2019.218859

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  20 in total

1.  Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL.

Authors:  Giovanni Palladini; Francesca Lavatelli; Paola Russo; Stefano Perlini; Vittorio Perfetti; Tiziana Bosoni; Laura Obici; Arthur R Bradwell; GianVico Melzi D'Eril; Roberto Fogari; Remigio Moratti; Giampaolo Merlini
Journal:  Blood       Date:  2006-01-24       Impact factor: 22.113

2.  Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach.

Authors:  Giovanni Palladini; Paolo Milani; Andrea Foli; Laura Obici; Francesca Lavatelli; Mario Nuvolone; Riccardo Caccialanza; Stefano Perlini; Giampaolo Merlini
Journal:  Haematologica       Date:  2013-11-08       Impact factor: 9.941

Review 3.  Systemic immunoglobulin light chain amyloidosis.

Authors:  Giampaolo Merlini; Angela Dispenzieri; Vaishali Sanchorawala; Stefan O Schönland; Giovanni Palladini; Philip N Hawkins; Morie A Gertz
Journal:  Nat Rev Dis Primers       Date:  2018-10-25       Impact factor: 52.329

4.  A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis.

Authors:  Ashutosh D Wechalekar; Stefan O Schonland; Efstathios Kastritis; Julian D Gillmore; Meletios A Dimopoulos; Thirusha Lane; Andrea Foli; Darren Foard; Paolo Milani; Lisa Rannigan; Ute Hegenbart; Philip N Hawkins; Giampaolo Merlini; Giovanni Palladini
Journal:  Blood       Date:  2013-03-11       Impact factor: 22.113

5.  A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis.

Authors:  Giovanni Palladini; Ute Hegenbart; Paolo Milani; Christoph Kimmich; Andrea Foli; Anthony D Ho; Marta Vidus Rosin; Riccardo Albertini; Remigio Moratti; Giampaolo Merlini; Stefan Schönland
Journal:  Blood       Date:  2014-08-12       Impact factor: 22.113

6.  A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis.

Authors:  Giovanni Palladini; Sajitha Sachchithanantham; Paolo Milani; Julian Gillmore; Andrea Foli; Helen Lachmann; Marco Basset; Philip Hawkins; Giampaolo Merlini; Ashutosh D Wechalekar
Journal:  Blood       Date:  2015-05-18       Impact factor: 22.113

7.  Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis.

Authors:  Giovanni Palladini; Carlo Campana; Catherine Klersy; Alessandra Balduini; Giovanbattista Vadacca; Vittorio Perfetti; Stefano Perlini; Laura Obici; Edoardo Ascari; Gianvico Melzi d'Eril; Remigio Moratti; Giampaolo Merlini
Journal:  Circulation       Date:  2003-04-28       Impact factor: 29.690

8.  Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins.

Authors:  Angela Dispenzieri; Robert A Kyle; Morie A Gertz; Terry M Therneau; Wayne L Miller; Krishnaswamy Chandrasekaran; Joseph P McConnell; Mary F Burritt; Allan S Jaffe
Journal:  Lancet       Date:  2003-05-24       Impact factor: 79.321

9.  Prognostic restaging at the time of second-line therapy in patients with AL amyloidosis.

Authors:  Yi L Hwa; Morie A Gertz; Shaji K Kumar; Martha Q Lacy; Francis K Buadi; David Dingli; Prashant Kapoor; Steve R Zeldenrust; Nelson Leung; Susanne R Hayman; Wilson I Gonsalves; Taxiarchis V Kourelis; Rahma Warsame; Ronald S Go; Eli Muchtar; Miriam A Hobbs; Amie L Fonder; Stephen Russell; Robert A Kyle; S Vincent Rajkumar; Angela Dispenzieri
Journal:  Leukemia       Date:  2019-02-08       Impact factor: 11.528

10.  Performance analysis of AL amyloidosis cardiac biomarker staging systems with special focus on renal failure and atrial arrhythmia.

Authors:  Tobias Dittrich; Axel Benner; Christoph Kimmich; Fabian Aus dem Siepen; Kaya Veelken; Arnt V Kristen; Tilmann Bochtler; Hugo A Katus; Carsten Müller-Tidow; Ute Hegenbart; Stefan O Schönland
Journal:  Haematologica       Date:  2019-01-17       Impact factor: 9.941
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.